Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors-Reference-Cited by-同舟云学术

Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors

Published:2007-02 Issue:2 Volume:31 Page:211-220
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Biedermann Bjoern,Gil Diana,Bowen David T.,Crocker Paul R.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference28 articles.

1. Mechanisms controlling pathogenesis and survival of leukemic stem cells;Jordan;Oncogene,2004

2. Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group;Bennett;Br J Haematol,1976

3. World Health Organization classification of the acute leukemias and myelodysplastic syndrome;Bennett;Int J Hematol,2000

4. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia;Taussig;Blood,2005

5. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance;Linenberger;Leukemia,2005

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells;Cancer Immunology Research;2024-04-25

2. Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window;Molecular Cancer Therapeutics;2024-04-01

3. Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191;Cancers;2024-02-22

4. Impact of the Siglec-Sialoglycan Axis on the Cancer Immune Response;Interdisciplinary Cancer Research;2024

5. Siglec-9 is an inhibitory receptor on human mast cells in vitro;Journal of Allergy and Clinical Immunology;2023-09